Overview

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Status:
Completed
Trial end date:
2017-10-26
Target enrollment:
Participant gender:
Summary
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with Overweight or Obesity.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S